Vestal Point Capital LP Buys New Holdings in Danaher Corporation $DHR

Key Points

• Vestal Point Capital LP has made a significant new investment in Danaher Corporation, purchasing 125,000 shares valued at approximately $25.6 million, which represents 1.8% of its portfolio.
• Danaher received mixed ratings from analysts, with target prices ranging from $205 to $250, indicating a generally positive outlook with a majority of analysts rating it as a Buy.
• In its latest earnings report, Danaher reported earnings per share of $1.80, beating analysts' expectations and reflecting a 3.4% increase in revenue year-over-year.

Vestal Point Capital LP acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 125,000 shares of the conglomerate's stock, valued at approximately $25,625,000. Danaher accounts for 1.8% of Vestal Point Capital LP's investment portfolio, making the stock its 19th largest position.

Other institutional investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth approximately $27,000. GHP Investment Advisors Inc. lifted its stake in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the period. Sierra Ocean LLC lifted its stake in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in shares of Danaher in the 1st quarter worth approximately $31,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after purchasing an additional 67 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Wells Fargo & Company reduced their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Evercore ISI cut their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Robert W. Baird raised their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Finally, Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.10% of the company's stock.

Danaher Stock Up 0.6%

Shares of DHR stock traded up $1.29 during trading hours on Friday, reaching $200.32. 2,837,584 shares of the company's stock were exchanged, compared to its average volume of 2,859,442. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The stock has a market cap of $143.44 billion, a PE ratio of 42.62, a PEG ratio of 2.78 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's fifty day moving average price is $201.93 and its two-hundred day moving average price is $199.41.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the previous year, the firm earned $1.72 earnings per share. The company's revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.